Abliva AB (publ) (NEVPF)
Abliva AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SE. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $45.1M. On trailing twelve-month figures it carries a trailing P/E of -2.95, a net margin of -69714.6%. Its beta of 0.75 implies it has historically moved less than the broad market.
Abliva AB (publ) is a pharmaceutical firm focused on developing novel treatments for primary mitochondrial disorders. Its product pipeline features KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions. Another compound, NV354, is undergoing preparations for clinical studies, specifically targeting primary mitochondrial diseases linked to Complex I deficiency. Beyond mitochondrial diseases, the company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for traumatic brain injury. Abliva collaborates with a range of institutions and companies, including Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. Founded in 2000 and based in Lund, Sweden, the company adopted its current name, Abliva AB (publ), in May 2020, having previously operated as NeuroVive Pharmaceutical AB (publ).
Abliva AB (publ) is most often compared with the following Healthcare names: